Concomitant use of high-dose methotrexate and glycyrrhizin affects pharmacokinetics of methotrexate, resulting in hepatic toxicity

Kentaro Abe, Tsukasa Higurashi, Mio Takahashi, Ayako Maeda-Minami, Yohei Kawano, Satoru Miyazaki, Yasunari Mano

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background/Aim: High-dose methotrexate is a therapy for acute leukemia, malignant lymphoma, and osteosarcoma. Glycyrrhizin has been used to treat hepatic dysfunction caused by high-dose methotrexate. However, few studies have investigated the interaction between glycyrrhizin and high-dose methotrexate. Materials and Methods: Male Wistar rats were treated with high-dose methotrexate (500 or 1,000 mg/kg) alone, or with co-administration of 100 mg/kg glycyrrhizin. Plasma concentrations of methotrexate, alanine aminotransferase, aspartate aminotransferase, and total bilirubin were measured. Results: At both methotrexate doses, the blood concentration of methotrexate was significantly increased and total clearance was significantly reduced using co-administration of glycyrrhizin compared with methotrexate alone, which led to increased levels of hepatic enzymes. These results suggest that glycyrrhizin significantly increases the plasma level and delays the clearance of methotrexate, resulting in hepatic toxicity. Conclusion: The concomitant use of methotrexate and glycyrrhizin should be considered with caution.

Original languageEnglish
Pages (from-to)2163-2169
Number of pages7
JournalIn Vivo
Volume35
Issue number4
DOIs
Publication statusPublished - Aug 2021

Keywords

  • Blood concentration
  • Glycyrrhizin
  • Hepatic dysfunction
  • High-dose methotrexate (HD-MTX)
  • Pharmacokinetic interactions
  • Rat

Fingerprint

Dive into the research topics of 'Concomitant use of high-dose methotrexate and glycyrrhizin affects pharmacokinetics of methotrexate, resulting in hepatic toxicity'. Together they form a unique fingerprint.

Cite this